Report of the Relapsed/Refractory Cohort of SWOG S0919: A Phase 2 Study of Idarubicin and Cytarabine in Combination with Pravastatin for Acute Myelogenous Leukemia (AML)

Inhibition of cholesterol synthesis and uptake sensitizes acute myeloid leukemia (AML) blasts to chemotherapy. A Phase 2 study of high dose pravastatin given in combination with idarubicin and cytarabine demonstrated an impressive response rate [75% complete remission (CR), CR with incomplete count...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Leuk Res
Autori principali: Advani, Anjali S., Li, Hongli, Michaelis, Laura C., Medeiros, Bruno C., Liedtke, Michaela, List, Alan F., O’Dwyer, Kristen, Othus, Megan, Erba, Harry P., Appelbaum, Frederick R.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2018
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6574123/
https://ncbi.nlm.nih.gov/pubmed/29407182
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.leukres.2018.01.021
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi